Berkshire Hathaway Eyes Bigger Stakes in Japan’s Top Trading Houses 
US Stock Futures Rally as Markets Digest Fed Rate Hike 
US Court Approves airBaltic Chapter 11 Restructuring 
Westinghouse Targets $50 Billion Valuation in U.S. IPO 
Holtec Nuclear Postpones $900 Million U.S. IPO 
European Stocks Rally After Fed Hike, Iran Peace Hopes 
Strait of Hormuz Oil Shipments Hit Six-Month High as U.S. Clears Mines 
BOJ Raises Interest Rate to 31-Year High as Yen Weakens 
Supertanker Orders Surge as US-Iran War Reshapes Oil Trade 
FCC Approves Foreign Investment in $110B Paramount-Warner Bros. Deal 
NASA, Boeing Discuss Expanding Starliner Missions 
Gold Prices Rise as Oil and Treasury Yields Fall 
Venezuela Nears Deal to Move $4 Billion in Gold to New York Fed 
Volvo Cars Plans 13 New Models by 2030 to Boost Sales 
Nike Earnings at Risk as UBS Cuts Price Target to $42 
American Airlines Eyes Capacity Cuts as High Fuel Prices Persist 
US Federal Register Drops Alibaba Qwen AI Search Tool 
Add as a preferred source on Google
Bristol Myers Squibb has been sued for $6. 4 billion for allegedly delaying a cancer drug. In the new lawsuit, it was claimed that the American multinational pharmaceutical company headquartered in New York improperly held up the development of a medicine for the treatment of non-Hodgkin's lymphoma.
The allegation against the pharma company
According to Reuters, it was alleged that Bristol Myers Squibb deliberately delayed the development so it can avoid paying $6.4 billion to Celgene Corp. shareholders. Bristol Myers acquired this drug manufacturing company in 2019.
Based on the complaint that was filed at the Manhattan federal court on Thursday, June 3, the company would have owed the said amount if it had received the approval from the U.S. Food and Drug Administration for specified deadlines for three drugs that Celgene had been developing.
In the filing, it was stated that the pharmaceutical company failed to use contractually required "diligent efforts" to get the FDA’s approval for the cancer drug called Breyanzi before the set deadline of Dec. 31, 2020. Now, with no approval before the deadline, the company was excused from paying the sum to Celgene.
It was reported that the lawsuit was filed by the UMB Bank NA, which is acting as a trustee for Celgene’s former shareholders. Bristol-Myers acquired Celgene under a $80.3 billion deal that was signed in November 2019.
Bristol Myers Squibb accused of misconduct
The former shareholders think that Bristol Myers did not exert efforts to beat the deadline when it was supposed to get the FDA’s approval for Breyanzi. They are suspecting that the company did this deliberately to avoid paying them, so they are accusing Bristol Myers of “blatant misconduct,” as per Fierce Pharma.
Finally, the case against Bristol Myers was recorded under 1:21-cv-04897 in the U.S. District Court-Southern New York. The shareholders that were represented by UMB Bank NA sued the pharma firm for breaching the CVR agreement through its failure to exert efforts to secure the needed approval from the FDA.
